TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00425113

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood Draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CT Scan
Study: NCT03128359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT00425113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PET Scan
Study: NCT02126670

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACT01

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT01

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT01

Intervention type: DRUG
Group type: OTHER
Intervention: ACT01

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comp01

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comp02

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comp03

Intervention type: DRUG
Group type: OTHER
Intervention: Comp04
Study: NCT03620253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
Study: NCT01123148

Intervention type: DEVICE
Group type: OTHER
Intervention: Using a BCI to control wheelchair tilt
Description: Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
Study: NCT03460652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP415 oral capsule
Description: Once-daily oral dose
Study: NCT03620253

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
Study: NCT01781377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROPOFOL
Description: PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROPOFOL
Description: PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
Study: NCT03256409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence mold and yeast and mesophyll aerobe
Description: Adherence mold and yeast and mesophyll aerobe to BOD and BJOD Microbial populations have been controlled in the saliva at initial time and adherence at 30 - 180 days after the overdentures in the mouth. The saliva sample was obtained from the patient in a sterile sputum collection bottle through a sterile solution. The overdenture samples were extracted and processed for analysis. Each sample was submerged in ¼ sterile Ringer and subjected to vigorous ultrasound shaking. From each of the microbial suspensions, successive dilutions were made to determine the total number of viable microorganisms present. Total count of mold and yeast and total count of mesophyll aerobe were performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence mold and yeast and mesophyll aerobe
Description: Adherence mold and yeast and mesophyll aerobe to BOD and BJOD Microbial populations have been controlled in the saliva at initial time and adherence at 30 - 180 days after the overdentures in the mouth. The saliva sample was obtained from the patient in a sterile sputum collection bottle through a sterile solution. The overdenture samples were extracted and processed for analysis. Each sample was submerged in ¼ sterile Ringer and subjected to vigorous ultrasound shaking. From each of the microbial suspensions, successive dilutions were made to determine the total number of viable microorganisms present. Total count of mold and yeast and total count of mesophyll aerobe were performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface Roughness (Ra)
Description: The surface roughness of BOD and BJOD was determined with the rugosimeter the Mitutoyo Surfest SJ-301® (Mitutoyo Corporation Inc., Kanagawa, Japan), through a displacement force of 4mN and of the tray to 0.5 mm/s and back to 1 mm/s (Murtra and Arcís,1999). The roughness profile Ra was evaluated and determined in microns (ųm) through five readings for each of the samples in the study respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface Roughness (Ra)
Description: The surface roughness of BOD and BJOD was determined with the rugosimeter the Mitutoyo Surfest SJ-301® (Mitutoyo Corporation Inc., Kanagawa, Japan), through a displacement force of 4mN and of the tray to 0.5 mm/s and back to 1 mm/s (Murtra and Arcís,1999). The roughness profile Ra was evaluated and determined in microns (ųm) through five readings for each of the samples in the study respectively.
Study: NCT01781377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METOCLOPRAMIDE
Description: METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METOCLOPRAMIDE
Description: METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: SALINE INFUSION
Study: NCT00720694

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duolith SD1
Study: NCT02904525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7 Tesla MRI, no contrast agent
Description: Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
Study: NCT01934933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celebrex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel
Study: NCT00720694

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Duolith SD1
Study: NCT04645992

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active TENS
Description: study group will receive only one session of yoga eye exercise for 20 minutes followed by TENS by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TENS
Description: control group will be treated with the same protocol as the study group but with the TENS unit is off .
Study: NCT00535769

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electronic + no text message
Description: Electronic monitor is attached but no text-messages are sent through cellular phones

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic monitor + text messages
Description: Electronic monitor is attached and text messages are sent through cellphone to remind sunscreen use
Study: NCT02988544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artificial shrinkage
Description: Artificial shrinkage of blastocyst
Study: NCT01934933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel plus Celebrex
Study: NCT04718584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)
Description: All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
Study: NCT03009240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01559415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal replacement diet using Modifast
Description: modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal diet combined with Modifast diet
Description: Combination of modifast and regular diet (1250 kcal/d) for 3 months
Study: NCT01232439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid receptor kappa antagonist
Description: Starting dose of 2 mg, administered orally, once.~The potential dose range for this study is 0.2 mg to 30 mg
Study: NCT03009240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01367314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVC-422
Description: Dermal Gel applied 3 times per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVC-422
Description: Dermal Gel applied 3 times per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVC-422
Description: Dermal Gel applied 3 times per day for 7 days
Study: NCT00003595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Study: NCT02453698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, \& Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose Placebo
Study: NCT00003595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Study: NCT01269632

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sampling, specific biological exams and biobank and self administered questionnaires
Description: HIV INFECTION at inclusion and annually up to 06 years follow-up~1. clinical and therapeutic evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires~In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)~HIV UNINFECTED at inclusion and after 3 years follow up~1. clinical evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sampling, specific biological exams and biobank and self administered questionnaires
Description: HIV INFECTION at inclusion and annually up to 06 years follow-up~1. clinical and therapeutic evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires~In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)~HIV UNINFECTED at inclusion and after 3 years follow up~1. clinical evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires
Study: NCT00003595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study: NCT02407743

Intervention type: BEHAVIORAL
Intervention: Surgical patients' clinical progression
Description: Study the dynamic nature of pain

Intervention type: GENETIC
Intervention: Genetic markers
Description: Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
Study: NCT00670566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irbesartan/hydrochlorothiazide
Description: 50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
Study: NCT03417310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H joystick
Description: A joystick that corrects lateral displacement and angulation for multi-direction reduction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Common reduction methods
Description: Manual reduction methods without the assistance of any devices
Study: NCT00003595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study: NCT01146613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 0.5mg capsules x 2, 2x a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical matched placebo x 2, 2xday, 13 weeks
Study: NCT02543853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: direct trocar entry
Description: direct trocar entry to provide pneumoperitoneum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: veres needle entry
Description: veres needle entry to provide pneumoperitoneum
Study: NCT01004536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silicone gel
Description: twice daily application onto designated half of cesarean section wound for 12 weeks
Study: NCT00003595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT01004536

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no treatment
Description: left untreated during the study period
Study: NCT00104988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 75 mg/m\^2/day PO daily for 6 weeks followed by a 2-week break

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 200 mg/day PO daily
Study: NCT00579423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Description: * Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.~* Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.~* Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient.
Study: NCT03439046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
Study: NCT03046446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Single intra-articular injection
Study: NCT03374358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .
Study: NCT00305448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250 intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250 intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular injection
Study: NCT00417768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
Study: NCT06268002

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vernonia cinerea
Description: Vernonia cinerea is an herb that is claimed in many Thai medicinal formulas. In traditional medicines, they use this herbal to treat diseases such as hypertension, asthma, fever, hepatitis, gallstones, including use to help smoker quit smoking.
Study: NCT02830243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
Study: NCT00839566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: AV-node ablation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Rate control by drug
Study: NCT01537315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
Study: NCT00003595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study: NCT02255617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal transplant processed from routinely screened universal donors
Study: NCT00742625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study: NCT00067821

Intervention type: DRUG
Intervention: 2-Flourodeoxyglucose
Study: NCT00742625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT01306643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablet(s) administered orally twice daily
Study: NCT03218839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex male circumcision device
Description: PrePex non-surgical male circumcision device applied to eligible, consenting HIV-infected men in Zimbabwe to determine the rate of adverse events as compared to non HIV-infected men.
Study: NCT00129285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Modafinil
Description: modafinil 200 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Modafinil
Description: modafinil 400 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 400 mg/day
Study: NCT02848092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCAL+
Description: Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rules of The road
Description: Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
Study: NCT04709003

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic test
Description: A blood test to check antibodies type and amount
Study: NCT00937131

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Rituximab
Description: Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
Study: NCT03021369

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pleural drainage system
Description: Pleural drainage system is connected to the chest tubes after surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pleural drainage system
Description: Pleural drainage system is connected to the chest tubes after surgery.